For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Survey respondents preferred patient portal messages written by AI, but their satisfaction decreased when they were told that messages were written by AI.

There appears to be a connection between prenatal per- and polyfluoroalkyl substance (PFAS) serum concentrations and some childhood cancers.

Implementing opportunistic computed tomography bone density screening could increase the osteoporosis screening rate, yielding a reduction in medical costs.

A retrospective population-based study showed that severe obesity and bariatric surgery independently increased the risk of inflammatory bowel disease.

Patients undergoing postmastectomy breast reconstruction (PMBR) have lower Sexual Well-Being scores than those undergoing breast-conserving therapy (BCT).

High-intensity interval training was associated with improved glycemic control and cardiometabolic outcomes among patients with type 2 diabetes.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Comorbid lung function impairment was associated with increased risks for cardiovascular disease and mortality in type 2 diabetes.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Patients with chronic kidney disease (CKD) and heart failure have higher rates of inpatient dialysis initiation than those without heart failure.